Biosimilars Program

In addition to developing novel biotherapeutics via the TRIDENT^™ platform, Oncobiologics is leveraging its scientific talent and technical infrastructure to advance biosimilar versions of therapeutically-important and commercially-attractive mAb biotherapeutics.

With a unique CMC engine designed to provide scientific rigor, speed and cost efficiencies, Oncobiologics is positioned to deliver a robust CMC package as required by the EMA and the recent draft guidance released by the US FDA.

Oncobiologics has established regional development and commercialization alliances for several regions around the world and is actively open to discussions for additional partnerships.